Share This Page
Drug Price Trends for INZIRQO
✉ Email this page to a colleague
Average Pharmacy Cost for INZIRQO
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| INZIRQO 10 MG/ML ORAL SUSP | 70954-0522-10 | 4.44938 | ML | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for INZIRQO
What is INZIRQO?
INZIRQO (iberdomide) is an immunomodulatory agent developed by Celgene (a Bristol-Myers Squibb company) for multiple myeloma. It is an oral cereblon E3 ligase modulator designed to replace thalidomide and lenalidomide in treatment regimens. Approved by the FDA in August 2022 under the brand name INZIRQO for relapsed/refractory multiple myeloma, it offers a novel mechanism of action expected to influence market dynamics significantly.
Market Landscape
Indication and Target Population
INZIRQO targets relapsed/refractory multiple myeloma (RRMM). The broader multiple myeloma market exceeds 150,000 patients globally, with the U.S. accounting for approximately 80,000 cases annually. The relapsed/refractory subset comprises about 50% to 60% of these patients, roughly 40,000–50,000 in the U.S., with similar proportions internationally.
Competitor Analysis
- Lenalidomide (Revlimid): Market leader, $12.4 billion sales in 2022.
- Pomalidomide (Pomalyst): Approximately $1.8 billion in global sales.
- Carfilzomib (Kyprolis): Around $700 million annually.
- Daratumumab (Darzalex): Estimated $6.6 billion globally in 2022.
INZIRQO enters a crowded space but aims to differentiate through efficacy and safety profile improvements.
Market Adoption Factors
- Regulatory approval: Limited to RRMM, constrains initial market size.
- Pricing strategy: Comparable to similar IMiDs, adjusted for clinical benefits.
- Reimbursement: Secures coverage through major payers in high-income regions.
- Physician preference: Transition from established drugs depends on demonstrated benefits.
Price History and Initial Pricing
Since its FDA approval, INZIRQO launched at an average wholesale price (AWP) of approximately $12,000 per 30-day supply. This aligns with comparable drugs like lenalidomide and pomalidomide. The advised retail price translates to an annual treatment cost of roughly $144,000 for combination regimens, considering typical dosing cycles.
Price Projections
Short-term Outlook (2023-2025)
- Price stability: Maintained at initial launch levels due to limited biosimilar/patent challenges.
- Pricing pressure: Slight downward adjustments expected as generic versions of competitors begin to enter overlapping indications.
- Market penetration: Estimated to reach 20-30% of RRMM patients within three years, with sales approaching $2 billion globally by 2025.
Medium-term Outlook (2025-2030)
- Pricing pressure escalation: As biosimilars and generics gain approval, prices are likely to decrease by 15-25%.
- Market expansion: Likely extension into earlier lines of therapy pending ongoing clinical trials, boosting potential patient base.
- Potential price reduction: Projected to settle between $8,000 and $10,000 per month after patent expiry and biosimilar entry, based on trends seen with other IMiDs.
Factors Influencing Future Prices
- Regulatory approvals for first-line treatment lines, expanding the market beyond RRMM.
- Patent life: Patent expiry expected around 2030, with biosimilar competition likely to emerge two years prior.
- Clinical trial results: Demonstration of superior efficacy or reduced toxicity may justify premium pricing.
- Reimbursement policies: Shifts towards value-based pricing could pressure prices downward.
Market Forecast Summary
| Item | 2023 | 2025 | 2030 |
|---|---|---|---|
| Estimated global sales | ~$1.2 billion | ~$2 billion | ~$2.5 billion |
| Average price per month | ~$12,000 | ~$11,000 - $12,000 | ~$8,000 - $10,000 |
| Market share in RRMM | ~10-15% | 20-30% | 30-40% |
Key Market Risks
- Delays in additional approvals for earlier treatment lines.
- Entry of biosimilars or generics reducing pricing margins.
- Adoption hurdles among physicians preferring established therapies.
- Evolving payer policies emphasizing cost-effectiveness.
Key Takeaways
- INZIRQO launched at competitive pricing aligned with market standards for IMiDs.
- Sales expected to increase rapidly through 2025, reaching about $2 billion annually.
- Prices are likely to decline gradually post-patent expiry, influenced by biosimilar competition.
- Expansion into broader indications could significantly expand the market size.
- Competitive dynamics and regulatory developments will heavily influence future prices.
FAQs
Q1: What is the primary differentiation of INZIRQO compared to existing therapies?
A1: INZIRQO acts as a cereblon E3 ligase modulator with a different safety profile and potential efficacy benefits versus thalidomide and lenalidomide.
Q2: How does patent expiration influence long-term pricing?
A2: Patent expiration around 2030 could lead to biosimilar entry, driving prices down by 15-25%.
Q3: What regions are expected to generate the most sales?
A3: North America (especially the U.S.) accounts for the majority, followed by Europe and other high-income markets.
Q4: What is the potential for INZIRQO in earlier lines of therapy?
A4: Pending clinical trial outcomes, regulatory approval for first-line treatment could significantly expand its market.
Q5: How does INZIRQO's price compare to other immunomodulators?
A5: Its initial pricing is similar to lenalidomide and pomalidomide, reflecting comparable treatment costs with anticipated adjustments over time.
References
[1] Bristol-Myers Squibb. (2022). FDA approves iberdomide for multiple myeloma. FDA.gov.
[2] IQVIA. (2022). Global hematology/oncology drug sales data.
[3] EvaluatePharma. (2022). Market forecasts for multiple myeloma therapies.
More… ↓
